Author: Ken Dropiewski

DiaMedica Therapeutics Appoints David Wambeke as Chief Business Officer

In Conjunction with His Appointment, Mr. Wambeke Purchased $750,000 of Common Shares from DiaMedica in a Private Placement Priced Above Market MINNEAPOLIS–(BUSINESS WIRE)–DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing a novel treatment for acute ischemic stroke (AIS), today announced the appointment of David Wambeke, as […]

Attune Medical and Heart Rhythm Clinical Research Solutions (HRCRS) Collaborate with Real World Evidence Consortium Members to Evaluate ensoETM™ in High Volume Centers

Real world study will investigate throughput and patient experiences with proactive esophageal cooling. CHICAGO–(BUSINESS WIRE)–Attune Medical and Heart Rhythm Clinical Research Solutions (HRCRS) are partnering on an evaluation of Attune’s ensoETM thermal regulating device through the HRCRS Real World Evidence (RWE) consortium. HRCRS will conduct a multi-center observational study through the RWE network of […]

AVS Appoints Sean Gilligan as Chief Operating Officer

30-year medical device veteran to lead AVS’ operational direction after long tenure with Boston Scientific BOSTON–(BUSINESS WIRE)–AVS, an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its PIVL™ therapy, announced the appointment of Sean Gilligan as the company’s new Chief Operating Officer. He […]

Acticor Biotech: Disclosure of The Total Number of Voting Rights and Shares as of March 31, 2023

PARIS–(BUSINESS WIRE)–Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, including ischemic stroke, today discloses the total number of voting rights and shares as of March 31, 2023 (pursuant to Article L. 233-8 II of […]

“Vesteck, Inc. Successfully Completes Five Clinical Cases”

WEST CHESTER, Pa., April 6, 2023 /PRNewswire/ — VESTECK, Inc. is pleased to announce the successful completion of 2 additional clinical cases with the “SUTURE-TIGHT” TM device. VESTECK, Inc., Scientific Advisory Board member Dr. Venkatesh Ramaiah along with Dr. Bao Bui, performed 2 EVAR procedures with the “SUTURE-TIGHT”TM catheter, helping patients number 4 and 5 in Sherbrook, Canada. […]

Icentia Receives U.S. Food and Drug Administration (FDA) Clearance for CardioSTAT®

QUEBEC CITY, April 6, 2023 /PRNewswire/ — Icentia Inc., today announced that it has received FDA 510(k) clearance for CardioSTAT, an ambulatory, continuous ECG monitoring solution that relies on a wire free, single-use recorder. “This approval marks a key milestone for our company. The FDA clearance opens the door to the world’s largest […]

HeartFlow, Leader in Revolutionizing Precision Heart Care, Closes $215 Million in Series F Funding Led by Bain Capital Life Sciences

Financing will further drive commercial scale for HeartFlow’s AI-enabled portfolio of precision heart care products MOUNTAIN VIEW, Calif., April 06, 2023 (GLOBE NEWSWIRE) — HeartFlow, Inc., the leader in revolutionizing precision heart care, today announced the close of a $215 million Series F funding round by its parent company HeartFlow […]

Occlutech Receives Subscription Commitment of Bonds Amounting to EUR 40 million in Nominal Value Under a Total Frame of EUR 75 million to Finance US Expansion and Growth

SCHAFFHAUSEN, CH / ACCESSWIRE / April 5, 2023 / Occlutech Holding AG Occlutech Holding AG (“Occlutech”), one of the world’s leading providers of minimally invasive structural heart disease devices, receives subscription commitment subject to certain conditions, of bonds to an aggregated amount of EUR 40 million. Bonds amounting to EUR 20 […]

AVS’s Pulsatile Intravascular Lithotripsy Technology Attracts an Additional $8.8M to Close $28.8M Series B Round

BioStar Capital led the round with CUE Growth Partners BOSTON, April 4, 2023 – AVS, an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its PIVL™ therapy, announced today that it closed an additional $8.8 million in new financing, bringing its Series B […]